Navigation Links
ADHD Medication Manufacturing in the US Industry Market Research Report from IBISWorld Has Been Updated
Date:2/9/2015

New York, NY (PRWEB) February 09, 2015

The ADHD Medication Manufacturing industry has exhibited robust growth, driven by the 42.0% increase in ADHD diagnoses over the past eight years, according to data from Healthline. In addition, according to data from IMS Institute for Healthcare Informatics, the top 20 therapeutic drug classes account for 42.0% of global pharmaceutical spending, which includes ADHD drugs. Moreover, data from IMS Health's National Prescription Audit revealed that the number of ADHD drugs dispensed in the United States has risen at an annualized rate of 6.1% to 80.0 million prescriptions from 2010 to 2013 (latest data available). “Overall, more ADHD drugs were dispensed over that period, due to strong demand from particular demographics, such as male individuals aged 12 to 18, according to Express Script's 2014 Turning Attention to ADHD report,” according to IBISWorld Industry Analyst Sarah Turk.

Due to ADHD being one of the most commonly diagnosed conditions for children in the United States, coupled with the recent recognition of ADHD as a condition that can also afflict adults, these trends have provided a boon to the industry. During the five years to 2015, industry revenue is expected to increase at an annualized rate of 8.0% to $12.9 billion, including a 13.0% uptick in 2015. “In particular, healthcare reform requires healthcare insurance providers to cover mental health services, with the Patient Protection and Affordable Care Act (PPACA) requiring insurers to cover pediatric screenings and vaccinations, including behavioral health assessments,” says Turk. Overall, this trend will enable more children to access behavioral health services, resulting in more patients being able to have their ADHD identified and treated.

In the five years to 2020, industry revenue is forecast to grow. Due to the American Psychiatric Association establishing guidelines for diagnosing ADHD in adults in 2013, this trend will likely bolster utilization rates for ADHD drugs from adults over the next five years. However, some key brand-name ADHD drugs are forecast to lose their patent exclusivity, enabling more generic drugs to inundate the market and thus, intensifying price-based competition.

For more information, visit IBISWorld’s ADHD Medication Manufacturing in the US industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld
Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld industry Report Key Topics

This industry manufactures medications that treat people with attention deficits, such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD).

Industry Performance
Executive Summary
Key External Drivers
Current Performance
Industry Outlook
Industry Life Cycle
Products & Markets
Supply Chain
Products & Services
Major Markets
Globalization & Trade
Business Locations
Competitive Landscape
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Barriers to Entry
Major Companies
Operating Conditions
Capital Intensity
Key Statistics
Industry Data
Annual Change
Key Ratios

About IBISWorld Inc.
Recognized as the nation’s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.

Read the full story at http://www.prweb.com/releases/2015/02/prweb12501303.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
2. Mothers immunosuppressive medications not likely to put fetus at risk
3. Racial difference in blood clotting warrants a closer look at heart attack medications
4. Watchful Waiting Can Do the Job of BPH Medications For Some Men, From the November 2013 Harvard Men's Health Watch
5. Effect of reducing blood pressure with medications immediately following ischemic stroke
6. Depression in pregnancy: New study shows preferences for therapy over medication
7. Medication adherence after hospitalization for acute coronary syndrome
8. Staying on medication may not translate to avoiding readmission
9. Treating alcohol dependence: Medication plus therapy leads to longer abstinence
10. Healthconnect Selects Surescripts to Reduce Medication Errors
11. Pradaxa Bleeding Allegations Lawyer: Resource4thePeople Reports New Study May Produce Treatment to Reverse Anti-Clotting Medication Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , ... September 25, 2017 , ... Bobbie Horowitz was ... Osteoarthritis and multiple health issues. As a cabaret and theater producer, Horowitz would manage ... main source of transportation in New York City, so she had to take a ...
(Date:9/25/2017)... ... September 25, 2017 , ... Physician Partners of America ... at 5304 Main Street as an interventional pain management specialist. , Dr. Gorman ... He joins PPOA from private practice In Brooksville, Fla. His orthopedic background puts him ...
(Date:9/25/2017)... Charles, LA (PRWEB) , ... September 25, 2017 , ... ... in Lake Charles, LA. “I could not imagine doing anything else,” said Dr. Hebert. ... me each and every day. The interactions with my patients is what I look ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Majestic Unicorn”: a poignant ... “The Majestic Unicorn” is the creation of published author, Dayna Chantel, an artist and ... far and wide to march aboard the cypress ark-vessel. Male and female, no matter ...
(Date:9/25/2017)... VA (PRWEB) , ... September 25, 2017 , ... ... and Response Preconference Workshop, **Presented by FDAnews**, Nov. 1-3, 2017 – Bethesda, MD, ... drugmaker passed with flying colors. And then, on the tenth inspection it failed. ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
(Date:9/9/2017)... INDIANAPOLIS , Sept. 9, 2017  Eli Lilly ... key primary and secondary endpoint data for lasmiditan, an ... migraine, which demonstrated statistically significant improvements compared to placebo ... be highlighted today at the 18th Congress of the ... . "The data presented today demonstrate lasmiditan,s ...
(Date:9/7/2017)... STOCKHOLM , Sept. 7, 2017 NuvoAir ... Air Smart Spirometer, announced today a partnership with Novartis Pharma ... partnership solidifies NuvoAir,s position as the leading mobile spirometry platform ... respiratory patients. ... spirometry test ...
Breaking Medicine Technology: